Comparative Effects of Moxonidine on Bone Metabolism, Vascular and Cellular Aging in Hypertensive Postmenopausal Women

Osteopenia Clinical Trial

— COMPASS  

Official title:

Comparative Effects of Moxonidine and Bisoprolol on Bone Metabolism, Vascular and Cellular Markers of Aging, Blood Pressure in Hypertensive Postmenopausal Women (COMPASS)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02355821
• Other study ID #: MOXOC001
• Status: Completed
• Phase: N/A
• Start date: April 2015
• Est. completion date: July 10, 2018

Study information

• Verified date: August 2021
• Source: National Medical Research Center for Therapy and Preventive Medicine
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study evaluates the effect of moxonidine versus bisoprolol on collagen type 1 C-telopeptide in postmenopausal female patients with arterial hypertension and osteopenia.

Description:

Several experimental studies have demonstrated that moxonidine may lower the activity of Na+- independent Cl-/bicarbonate exchanger (anion exchanger, AE) which plays an essential role in viability of osteoclasts that are crucial for bone resorption. The suppression of AE proteins activity has been proven to inhibit osteoclast activity and reduce bone resorption whereas the moxonidine molecule is known to reduce the AE protein activity. Therefore, the results of experimental studies have shown the ability of moxonidine to inhibit bone resorption through its effect on the osteoclast activity.

Published data contain information on positive effects of beta-blockers on the bone tissue condition. There are data which clearly demonstrate a positive effect of beta-blockers on bone mass.

The proposed trial is a comprehensive study of moxonidine effects on processes of cellular and vascular aging as well as bone metabolism.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 114
• Est. completion date: July 10, 2018
• Est. primary completion date: June 15, 2018
• Accepts healthy volunteers: No
• Gender: Female
• Age group: N/A and older

Eligibility

Inclusion Criteria:

1. Female with age 45 years and older.

2. Postmenopausal (absence of menstrual periods for a minimum of 12 months) at the moment of Informed Consent sign.

3. Arterial hypertension grade I / II per ESH/ESC 2013 guidelines (diastolic pressure = 90 and <110 mm Hg, systolic pressure =140 and <180 mm Hg).

4. Not achieving BP targets <140/90 mmHg either during antihypertensive therapy or naive.

5. Absence of moxonidine or bisoprolol treatment at least 6 months before the study

6. Osteopenia of lumbar spine and/or proximal part of the femur (osteoporosis T-score from -1 to -2.5 standard deviations [SD]) by X-Ray densitometry.

7. Signed Informed Consent for participation in the study

-

Exclusion Criteria:

1. Hypersensitivity to moxonidine, bisoprolol or any other ingredient of the respective formulations

2. Any Contraindications for moxonidine, bisoprolol

3. Osteoporosis (?-score below - 2.5 SD).

4. Primary or secondary hyperparathyroidism.

5. Paget's disease of bones.

6. History of low traumatic bone fractures.

7. Malabsorption syndrome.

8. History of gastro-intestinal surgery.

9. Severe disturbance of peripheral circulation.

10. Raynaud's disease.

11. Symptomatic (secondary) hypertension (caused by any primary internal diseases)

12. Morbid obesity (BMI over 40 kg/m2).

13. Symptoms of estrogen deficiency such as hot flushes, nights sweat, vaginal dryness

14. Administration of any hormone-replacement therapy (HRT) or intake of isoflavones

15. Secondary hypogonadism.

16. Sistolic BP =180 mm Hg and/or Diastolic BP =110 mm Hg.

17. Clinical presentations of cardiovascular disease: coronary heart disease (CHD), history of stroke, transient ischemic attack (TIA), Charcot's syndrome.

18. Severe heart failure.

19. Hemodynamically significant congenital heart disease.

20. Heart rhythm disorders which require permanent use of any antiarrhythmic medications (including ß-adrenoblockers and calcium antagonists).

21. Diabetes mellitus of any genesis.

22. Severe liver failure.

23. Severe kidney failure including patients on dialysis

24. Thyroid diseases accompanied by functional disorders (thyrotoxicosis or uncompensated hypothyroidism).

25. Alcohol and drug abuse.

26. Patients with oncological diseases diagnosed within 5 years before IC execution.

27. Inability of the patient to comprehend the essence of the program and to provide his/her consent for participation in the program.

28. Patients with any condition, which in the opinion of the Investigator makes the patient unsuitable for inclusion based on clinical judgment.

29. Corticosteroid therapy

30. Participation in any other clinical study during the whole course of this investigation including participation in a study within 30 days prior to providing the informed consent for this trial

-

Related Conditions & MeSH terms

• Arterial Hypertension
• Bone Diseases, Metabolic
• Hypertension
• Osteopenia

Intervention

Drug:
• Moxonidine
0.4 mg moxonidine QD titration up to 0.6 mg moxonidine BID Other Names:perindopril 10 mg/day (optional); losartan 50 mg/day (optional); calcium carbonate; vitamin D
• Bisoprolol
5 mg Bisoprolol QD titration up to 7.5 mg Bisoprolol BID Other Names: perindopril 10 mg/day (optional); losartan 50 mg/day (optional); calcium carbonate; vitamin D

Locations

Country	Name	City	State
Russian Federation	National Research Center for Preventive Medicine	Moscow

Sponsors (1)

Lead Sponsor	Collaborator
National Research Center for Preventive Medicine

Country where clinical trial is conducted

Russian Federation, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Collagen Type 1 C-telopeptide	Changes in Median (Inter-Quartile Range) of the bone resorption marker (collagen type 1 C-telopeptide) at the end of the study from the baseline are evaluated in comparison between the groups	baseline (Visit 1) and 12 months (Visit 4)
Secondary	Osteocalcin	Changes in Median (Inter-Quartile Range) values of the bone synthesis marker (osteocalcin) at the end of the study (V4) from the baseline (V1) and to compare the values between the groups.	baseline (Visit 1) and 12 months (Visit 4)
Secondary	Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL).	Changes in Median (Inter-Quartile Range) values of the receptor activator of nuclear factor kappa-B ligand (RANKL) at final visit versus baseline level in comparison between the groups	baseline (Visit 1) and 12 months (Visit 4)
Secondary	Bone Mineral Density (BMD) Using Control Dual-energy X-ray Absorptiometry	Changes in Median (Inter-Quartile Range) values of Bone mineral density (BMD) at final visit versus baseline level using control dual-energy X-ray absorptiometry and in comparison between the groups	12 months
Secondary	Telomerase Activity	Changes in Median (Inter-Quartile Range) telomerase activity at final visit versus baseline level in comparison between the groups Telomerase activity is measured in arbitrary units. Currently, there are no established reference values for telomerase activity in the world. Its activity is considered high or low in relation to the median.	baseline (Visit 1) and 12 months (Visit 4)
Secondary	Pulse Wave Velocity (PWV)	Changes in mean pulse wave velocity (PWV) at final visit versus baseline level and in comparison between the groups	baseline (Visit 1) and 12 months (Visit 4)
Secondary	Intima-media Thickness (IMT)	Changes in mean intima-media thickness (IMT) at final visit in comparison between the groups.	baseline (Visit 1) and 12 months (Visit 4)
Secondary	THe Number (Percentage) of the Treatment Responders	Proportion of the treatment responders (defined as the proportion (%) of patients who achieved target blood pressure <140/90 mmHg) after 8 and 48 weeks of the investigated treatment (V2, V3 and V4) and to compare the values between the groups.	baseline (Visit 1) and 12 months (Visit 4)
Secondary	Number of Participants With Adverse Events (AE)	Number of Participants with Adverse Events (AE)	baseline (Visit 1) and 12 months (Visit 4)

External Links

•   The aim was to assess the effects of moxonidine in terms of target blood pressure achievement; to identify potential additional benefits of moxonidine and its effects on bone metabolism and bone mineral density in postmenopausal women
•   The review of a new data is provided related to novel aspects of moxonidine use in the patients with arterial hypertension. The main attention is paid to the problem of vascular ageing, telomere biology and calcium-phosphorus homeostasis